DeepMed Research

Peking University First Hospital (Peking Univesity First Medical School)

🇨🇳China

Country: 🇨🇳China

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Low-dose S-ketamine and Dexmedetomidine in Combination With Opioids for Postoperative Analgesia

Phase 4

Completed

Conditions: S-ketamine
Scoliosis Correction
Postoperative Analgesia
Dexmedetomidine
Sufentanil

Interventions: Drug: Sufentanil
Drug: S-ketamine
Drug: Dexmedetomidine

First Posted Date: 2021-03-10

Last Posted Date: 2022-12-13

Lead Sponsor: Peking University First Hospital

Target Recruit Count: 200

Registration Number: NCT04791059

Locations: 🇨🇳
Peking University First Hospital, Beijing, Beijing, China

Digital Cognitive Behavioral Therapy for Insomnia (dCBT-I) for Chronic Insomnia ：A Randomized Controlled Trial

Not Applicable

Completed

Conditions: Chronic Insomnia

Interventions: Behavioral: smartphone-based dCBT-I from a Wechat applet
Behavioral: sleep education

First Posted Date: 2021-03-03

Last Posted Date: 2022-12-07

Lead Sponsor: Peking University First Hospital

Target Recruit Count: 82

Registration Number: NCT04779372

Locations: 🇨🇳
Peking University First Hospital, Beijing, Beijing, China

Obstructive Sleep Apnea Influences Efficacy of PD-1-Based Immunotherapy Against Non-Small Cell Lung Cancer

Recruiting

Conditions: Non-small Cell Lung Cancer
Obstructive Sleep Apnea

First Posted Date: 2021-02-08

Last Posted Date: 2022-04-26

Lead Sponsor: Peking University First Hospital

Target Recruit Count: 200

Registration Number: NCT04743752

Locations: 🇨🇳
Peking University First Hospital, Beijing, Beijing, China

Multicomponent Prehabilitation and Outcomes in Elderly Patients With Frailty

Not Applicable

Recruiting

Conditions: Old Age; Debility
Nutrition Therapy
Outcomes
Surgery
Digestive Cancer
Preoperative Rehabilitation

Interventions: Dietary Supplement: Preoperative nutritional optimization
Behavioral: Preoperative exercise training
Behavioral: Postoperative exercise training

First Posted Date: 2021-01-20

Last Posted Date: 2023-08-01

Lead Sponsor: Peking University First Hospital

Target Recruit Count: 538

Registration Number: NCT04715581

Locations: 🇨🇳
Peking University First Hospital, Beijing, Beijing, China

Dexmedetomidine as an Adjuvant for Femoral Nerve Block and Functional Recovery After Total Knee Arthroplasty

Phase 4

Completed

Conditions: Elderly
Total Knee Arthroplasty
Functional Outcome
Femoral Nerve Block
Dexmedetomidine

Interventions: Drug: Placebo
Drug: Dexmedetomidine

First Posted Date: 2020-11-24

Last Posted Date: 2022-04-20

Lead Sponsor: Peking University First Hospital

Target Recruit Count: 170

Registration Number: NCT04642651

Locations: 🇨🇳
Beijing Jishuitan Hospital, Beijing, Beijing, China
🇨🇳
Peking University First Hospital, Beijing, Beijing, China

Observational Study of Camrelizumab Combined With Apatinib and Hyperfractionated Radiotherapy for Renal Cell Carcinoma

Conditions: Renal Cell Carcinoma

Interventions: Combination Product: camrelizumab+apatinib+hyperfractionated radiotherapy

First Posted Date: 2020-10-30

Last Posted Date: 2020-10-30

Lead Sponsor: Peking University First Hospital

Target Recruit Count: 30

Registration Number: NCT04609293

Dexmedetomidine Supplemented Analgesia in Patients at High-risk of Obstructive Sleep Apnea

Phase 4

Completed

Conditions: Obstructive Sleep Apnea
Analgesia
Dexmedetomidine
High-flow Nasal Cannula
Sleep Quality

Interventions: Drug: Placebo
Drug: Dexmedetomidine

First Posted Date: 2020-10-29

Last Posted Date: 2022-12-13

Lead Sponsor: Peking University First Hospital

Target Recruit Count: 152

Registration Number: NCT04608331

Locations: 🇨🇳
Dong-Xin Wang, Beijing, Beijing, China

Change Trend of Effluent Eosinophil During Peritoneal Dialysis-Related Peritonitis

Conditions: Peritonitis

First Posted Date: 2020-10-20

Last Posted Date: 2021-12-08

Lead Sponsor: Peking University First Hospital

Target Recruit Count: 100

Registration Number: NCT04594421

Locations: 🇨🇳
Renal Division and Institute of Nehprology,Peking University First Hospital, Beijing, Beijing, China

Combination of Hyperfractionated Radiotherapy With Immunotherapy in Massive Tumors

Conditions: Immunotherapy
Bulky Tumor
SBRT

Interventions: Combination Product: camrelizumab+hyperfractionated radiotherapy

First Posted Date: 2020-10-14

Last Posted Date: 2020-10-14

Lead Sponsor: Peking University First Hospital

Target Recruit Count: 60

Registration Number: NCT04587817

The Flash FFR Ⅱ Study

Not Applicable

Recruiting

Conditions: Coronary Artery Disease
Coronary Stenosis
Myocardial Ischaemia
Unstable Angina Pectoris
Asymptomatic Ischemia
Stable Angina Pectoris
Acute Myocardial Infarction
Percutaneous Coronary Intervention
Coronary Circulation

Interventions: Diagnostic Test: caFFR
Diagnostic Test: FFR

First Posted Date: 2020-10-05

Last Posted Date: 2023-03-21

Lead Sponsor: Peking University First Hospital

Target Recruit Count: 2132

Registration Number: NCT04575207

Locations: 🇨🇳
Zhongshan Hospital affiliated to Fudan University, Shanghai, Shanghai, China
🇨🇳
Department of Cardiology, Peking University First Hospital, Beijing, China
🇨🇳
Guangdong Provincial People's Hospital, Guangzhou, Guangdong, China

and more 10 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy